Dong Soo Lee1, Do Hoon Lim2, Il Han Kim3, Joo-Young Kim4, Jung Woo Han5, Keon Hee Yoo6, Kyung Duk Park7, Hyeon Jin Park8, Nack-Gyun Chung9, Chang-Ok Suh10, Dong-Seok Kim11. 1. Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea. 4. Department of Radiation Oncology, National Cancer Center, Goyang, Republic of Korea. 5. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea. 6. Department of Pediatrics, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 7. Department of Pediatrics, Seoul National University Hospital, Seoul, Republic of Korea. 8. Department of Pediatrics, National Cancer Center, Goyang, Republic of Korea. 9. Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 10. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: cosuh317@yuhs.ac. 11. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: dskim33@yuhs.ac.
Abstract
PURPOSE: To assess the efficacy of upfront chemotherapy followed by response-adapted reduced-dose/reduced-volume radiotherapy (RT) for intracranial germinoma. MATERIALS AND METHODS: Ninety-one patients from five institutions were registered in the KSPNO G051/G081 Protocol. Germinomas were classified as solitary or multiple/disseminated diseases, and upfront chemotherapy was administered. For all patients with multiple or disseminated disease, and patients with partial response after chemotherapy, 19.5-24 Gy of craniospinal irradiation plus 10.8-19.8 Gy of tumor bed boost were planned. For patients with complete response (CR), reduced-dose RT (30.6 Gy) was planned, along with a reduced field for solitary lesions. RESULTS: The median patient age was 14 (range, 3-30) years. Sixty-five patients (71.4%) had a solitary lesion. The median follow-up duration was 67.9 (range, 6.6-119.3) months. Recurrence was not observed in 32 patients in the protocol compliant group. Four patients (4.4%) in the protocol non-compliant group experienced relapse after CR and one patient died of the disease. The 5-year and 7-year overall survival rates were 98.8% and 98.8%, while the corresponding event-free survival rates were 96.6% and 93.8%, respectively. All three patients with basal ganglia germinomas who were treated with local RT experienced recurrence outside the RT field. Among the 23 patients with pineal or suprasellar lesions who received whole-ventricle RT, there was no recurrence. CONCLUSIONS: Currently used upfront chemotherapy followed by reduced-dose, reduced-volume RT appears acceptable, when whole-ventricle RT for pineal or suprasellar tumors and, at minimum, whole-brain RT for basal ganglia/thalamus lesions are applied.
PURPOSE: To assess the efficacy of upfront chemotherapy followed by response-adapted reduced-dose/reduced-volume radiotherapy (RT) for intracranial germinoma. MATERIALS AND METHODS: Ninety-one patients from five institutions were registered in the KSPNO G051/G081 Protocol. Germinomas were classified as solitary or multiple/disseminated diseases, and upfront chemotherapy was administered. For all patients with multiple or disseminated disease, and patients with partial response after chemotherapy, 19.5-24 Gy of craniospinal irradiation plus 10.8-19.8 Gy of tumor bed boost were planned. For patients with complete response (CR), reduced-dose RT (30.6 Gy) was planned, along with a reduced field for solitary lesions. RESULTS: The median patient age was 14 (range, 3-30) years. Sixty-five patients (71.4%) had a solitary lesion. The median follow-up duration was 67.9 (range, 6.6-119.3) months. Recurrence was not observed in 32 patients in the protocol compliant group. Four patients (4.4%) in the protocol non-compliant group experienced relapse after CR and one patientdied of the disease. The 5-year and 7-year overall survival rates were 98.8% and 98.8%, while the corresponding event-free survival rates were 96.6% and 93.8%, respectively. All three patients with basal ganglia germinomas who were treated with local RT experienced recurrence outside the RT field. Among the 23 patients with pineal or suprasellar lesions who received whole-ventricle RT, there was no recurrence. CONCLUSIONS: Currently used upfront chemotherapy followed by reduced-dose, reduced-volume RT appears acceptable, when whole-ventricle RT for pineal or suprasellar tumors and, at minimum, whole-brain RT for basal ganglia/thalamus lesions are applied.
Authors: Kyung Taek Hong; Da Hye Lee; Bo Kyung Kim; Hong Yul An; Jung Yoon Choi; Ji Hoon Phi; Jung-Eun Cheon; Hyoung Jin Kang; Seung-Ki Kim; Joo-Young Kim; Sung-Hye Park; Il Han Kim; Hee Young Shin Journal: BMC Cancer Date: 2020-10-09 Impact factor: 4.430
Authors: Joo Ho Lee; Keun-Yong Eom; Ji Hoon Phi; Chul-Kee Park; Seung Ki Kim; Byung-Kyu Cho; Tae Min Kim; Dae Seog Heo; Kyung Taek Hong; Jung Yoon Choi; Hyoung Jin Kang; Hee Young Shin; Seung Hong Choi; Soon Tae Lee; Sung Hye Park; Kyu-Chang Wang; Il Han Kim Journal: Cancer Res Treat Date: 2021-01-13 Impact factor: 4.679